Orthocell Posts Record U.S. Monthly Sales for Nerve Wrap Device
Orthocell's Remplir nerve wrap hit its highest U.S. monthly sales since launch in October 2026, signaling growing market traction.
Australian medical device maker Orthocell Ltd recorded its strongest month of U.S. sales for its Remplir collagen nerve wrap since the product's launch, with 92 units sold in October 2026, according to the company.
Remplir is an FDA-cleared collagen nerve wrap engineered to support the repair and protection of peripheral nerves. The device is designed and manufactured in Australia, and Orthocell has positioned it as an emerging category leader in key international markets.
Read more Pakistani Banks Score Below 2 Out of 10 on Climate Policy Tests →
The October milestone reflects accelerating commercial momentum for the product in the United States, one of the world's largest markets for peripheral nerve repair technologies. Peripheral nerve injuries can result from trauma, surgery, or disease, and demand for effective repair solutions has grown alongside advances in surgical technique.
Orthocell's ability to reach this sales record suggests the company is gaining broader acceptance among U.S. surgeons and health systems, a critical hurdle for foreign medical device firms seeking to establish durable footholds in the American market. Regulatory clearance from the FDA had already cleared a significant pathway for commercial adoption.
Continue reading at All Financial Services & Investing for the full company update and additional market context.
